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Background: In pancreatic ductal adenocarcinoma (PDAC), fractalkine receptor CX3CR1 contributes to perineural invasion (PNI).
We investigated whether CX3CR1 expression occurs early in PDAC and correlates with tumour features other than PNI.
Methods: We studied CX3CR1 and CX3CL1 expression by immunohistochemistry in 104 human PDAC and coexisting Pancreatic
Intraepithelial Neoplasia (PanIN), and in PdxCre/LSL-KrasG12D mouse model of PDAC. CX3CR1 expression in vitro was studied by
a spheroid model, and in vivo by syngenic mouse graft of tumour cells.
Results: In total, 56 (53.9%) PDAC expressed CX3CR1, 70 (67.3%) CX3CL1, and 45 (43.3%) both. CX3CR1 expression was
independently associated with tumour glandular differentiation (P¼ 0.005) and PNI (P¼ 0.01). Pancreatic Intraepithelial Neoplasias
were more frequently CX3CR1þ (80.3%, Po0.001) and CX3CL1þ (86.8%, P¼ 0.002) than matched cancers. The survival of PDAC
patients was better in those with CX3CR1þ tumour (P¼ 0.05). Mouse PanINs were also CX3CR1þ and -CL1þ . In vitro, cytokines
significantly increased CX3CL1 but not CX3CR1 expression. Differently, CX3CR1 was upregulated in tumour spheroids, and in vivo
only in well-differentiated tumours.
Conclusion: Tumour differentiation, rather than inflammatory signalling, modulates CX3CR1 expression in PanINs and PDAC.
CX3CR1 expression pattern suggests its early involvement in PDAC progression, outlining a potential target for interfering with
the PanIN transition to invasive cancer.
Pancreatic cancer, namely ductal adenocarcinoma (PDAC), is a
major health problem, the death rate approaching the incidence of
the disease (Hidalgo, 2010). The majority of PDACs are diagnosed
at an advanced stage, beyond any possibility of cure. A better
understanding of the early neoplastic changes in the pancreas
might help anticipating the diagnosis and counteracting the rapid
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progression of pancreatic cancer. Microscopic pre-cancerous
lesions (Pancreatic Intraepithelial Neoplasia, PanIN) house KRAS
mutations (Jones et al, 2008; Sipos et al, 2009) and accumulate
further gene damage along progression to cancer (Jones et al,
2008). However, gene damage is not the only driver of pancreatic
carcinogenesis, PDAC being characterised by a dense stromal
reaction, referred to as desmoplasia (Farrow et al, 2008), which is
an active partner in disease progression (Hwang et al, 2008;
Vonlaufen et al, 2008). Stromal cells produce cytokines and growth
factors that establish an active tumour-stroma cross-talk (Farrow
et al, 2008; Hwang et al, 2008; Vonlaufen et al, 2008). Mediators of
the cross-talk between cancer and microenvironment include
chemokines, small chemotactic cytokines, and their receptors
(Mantovani et al, 2008; Wang et al, 2008; Balkwill, 2012). Tumour
expression of chemotactic molecules modifies the behaviour of
cancer cells and tumour progression. The gain of expression of
chemokine receptors enhances cancer invasion and spread by
mediating cancer cell trafficking and metastasis homing
(Mantovani et al, 2010). Chemokine expression in cancer may
also affect immune recognition by the host, and may promote
autocrine loops favouring the survival of tumour cells (Wang et al,
2008; Balkwill, 2012). The expression of the chemokine receptor
CXCR4 has been associated with an enhanced progression of
PDAC, and with stemness of cells with metastatic potential
(Marchesi et al, 2004; Hermann et al, 2007). Surprisingly, the
expression of CXCR4 and of its ligand CXCL12 begins in the pre-
invasive stages of pancreatic neoplasia (Thomas et al, 2008). The
relevance of chemokine receptors in PDAC spread has been
recently strengthened by the finding that tumour cells also express
the chemokine receptor CX3CR1 (Marchesi et al, 2008). CX3CR1
forms a high-affinity axis (CX3-CR1-CL1) with its unique ligand
CX3CL1 (also referred to as Fractalkine/Neurotactin), a mucin-
chemokine hybrid expressed by endothelial cells and neurons,
either as a membrane-anchored adhesion molecule or as a secreted
chemoattractant (Bazan et al, 1997; Pan et al, 1997). CX3CR1
expression was associated with the degree of perineural invasion
(PNI), and PDAC cells expressing CX3CR1 were found to disrupt
peripheral nerves once xenografted in mice (Marchesi et al, 2008).
It is unknown whether the expression of the receptor occurs
already in pre-invasive stages of pancreatic carcinogenesis, or
alternatively, only in invasive cancer. Furthermore, limited
information is available as to the expression of the ligand in
PDAC (Xu et al, 2012), and as to whether tumour features and
microenvironment cross-talk may affect CX3-CR1-CL1 status.
This study was aimed to investigate whether pancreatic cancer
expresses CX3-CR1-CL1, already gaining the expression of these
chemotactic molecules in pre-invasive stages, and whether an
association exists with PDAC features and outcome. To these aims,
we assessed the expression of CX3-CR1-CL1 in human PanINs and
invasive cancers, as well as in PanINs of a Kras-mutated mouse
model of pancreatic cancer, and tested their responsiveness to
cytokines and their expression in tumours propagated in vivo.
MATERIALS AND METHODS
Patients and tissues specimens. We retrospectively retrieved the
tissue specimens from 104 patients who underwent resective
surgery for pancreatic cancer at the Humanitas Clinical and
Research Center, Rozzano, Milan, Italy. Seventy-six PDAC also
harboured precursor lesions.
For each patient included in the study, demographics and
complete pathological data at diagnosis were available. Specimens
were reviewed by pathologists unaware of molecular data. Tumour
pathological staging, histopathological typing, tumour grade, and
the presence or absence of PNI and/or of extramural vein invasion
were assessed in each PDAC. The absence of nodal involvement
was considered as appropriate only for PDAC in which X12
lymph nodes had been assessed. The study was conducted in
accordance with the guidelines of the Ethics Committee of the
Hospital, and the referring physician obtained the informed
consent of the patients to the treatment of their personal data at
the time of surgery. The overall survival (OS) was calculated from
diagnosis until death, and deceases were documented by obtaining
the death certificate in every case.
Mouse models of pancreatic cancer. Female and male mice
carrying mutated KrasG12D or Trp53R172H (C57BL/6;129SvJae
H-2b;d) under the endogeneous promoter and flanked by Lox-
STOP-Lox cassettes were bred by us (Hingorani et al, 2005).
PdxCre/LSL-KrasG12D and PdxCre/LSL-KrasG12D-Trp53R172H
double mutant mice, developing PDAC, were generated by crossing
them with C57BL/6 mice, expressing Cre recombinase, under a
specific pancreatic transcriptional factor Pdx-1 (pancreatic duode-
num homeobox 1) promoter. Mice were screened by PCR using tail
DNA amplified by specific primers to Lox-P cassette flanking K-ras
gene and Cre recombinase gene. Mice were kept under pathogen-
free conditions at the Molecular Biology Center, University of
Turin, and treated in accordance with European Union and
University of Turin Guidelines. Pancreata from wild-type or
PdxCre/LSL-KrasG12D mutant mice killed at 1, 6, and 9 months
from birth were subsequently fixed in formalin and embedded in
paraffin.
Immunohistochemistry. Two-mm-thick sections were processed
for immunohistochemistry (IHC). After deparaffining and rehydra-
tion, the sections were immersed in antigen retrieval bath, incubated
with 3% H2O2 for 15min, and treated for 2 h at room temperature
with primary antibodies raised against CX3CR1 (Ab8021, polyclonal
rabbit anti-human; Abcam, Cambridge, UK) and CX3CL1 (AF365,
polyclonal goat anti-human; R&D Systems, Minneapolis, MN,
USA), or with rabbit or goat IgG (Dako, Milan, Italy) to serve as
negative controls, followed by 30-min incubation with the DAKO
Envision system (Dako) or the Anti-Goat Polymer kit (Biocare, San
Francisco, CA, USA). Three-30-diaminobenzidine tetrahydrochlor-
ide (Dako) was used as a chromogen and nuclei were lightly
counterstained with haematoxylin (Medite, Bergamo, Italy).
Following IHC, in a subset of 15 PDAC harbouring CX3CR1þ
precursor lesions, PanINs were graded (54 PanIN-1, 43 PanIN-2, and
35 PanIN-3) and systematically evaluated for CX3CR1, CX3CL1, P16,
and E-Cadherin expression according to the degree of dysplasia. P16/
CDKN2A and E-Cadherin IHC was performed with mouse
monoclonal antibodies (Ab-7, 16P07; NeoMarkers Lab Vision,
Fremont, CA, USA and clone NCH38; Dako, respectively).
In pancreata obtained from five PdxCre/LSL-KrasG12D mutant
mice, CX3CR1 IHC was performed with the same antibody used
for human tissues, CX3CL1 expression was investigated by a
polyclonal rabbit anti-mouse antibody (Torrey Pines Biolabs, East
Orange, NJ, USA), and recognition of S-100þ neural structures
was achieved by monoclonal rabbit anti-mouse antibodies (Dako).
The intensity of CX3CR1 and CX3CL1 immunoreactivity was
independently evaluated by two researchers (FG and CG).
Immunoreactivity of infiltrating leukocytes and of endothelial cells
served as positive internal controls for CX3CR1 and for CX3CL1,
respectively. The semiquantitative evaluation of immunoreactivity
of neoplastic ductal cells was first attributed through a 0-to-3 score:
0 (absence of immunoreactivity), 1 (weak), 2 (moderate), and 3
(strong), according to the level of immunoreactivity of most
(X70%) neoplastic cells (Marchesi et al, 2008). Samples with 0–1
and with 2–3 immunoreactivity were subsequently pooled together,
in a binary classification.
CX3CR1 and CX3CL1 mRNA expression in human and mouse
ductal cell lines. Quantitative RT–PCR was employed to assess
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the expression of CX3CR1 and CX3CL1. Briefly, 1 ml of sample
cDNA was added to the PCR mixture containing 2X Power SYBR
Green Master Mix (Applied Biosystem, Life Technologies, Grand
Island, NY, USA) and specific primers (for CX3CR1, 50-GGGACT
GTGTTCCTGTCCAT-30 and CX3CR1 50-GACACTCTTGGG
CTTCTTGC-30; for CX3CL1 50-TGGCTGCTCCGCTTGGC-30,
and CX3CL1, 50-CCTGGTTCTGTTGATAGTGGATGAG-30);
18s RNA was used as a housekeeping gene. Data analysis was
performed by comparative Delta Ct (DDCt) method, and fold
change calculated using 2DDCt.
Primary mouse pancreatic cell lines DT6606 (obtained from a
tumour arisen in a PdxCre/LSL-KrasG12D mouse) and K8484
(obtained from a tumour arisen in a PdxCre/LSL-KrasG12D-
Trp53R172H mouse (Olive et al, 2009)) and human pancreatic
cancer cell line A8184, MiaPacaII and AspCI were maintained in
RPMI with 10% fetal bovine serum (FBS), 100mgml 1 of
penicillin G, 50mgml 1 of Streptomycin and Ultraglutamine
2mM and growth at 37 1C, 5% CO2 incubator. Cells seeded at
106 cells per ml in six-well plates were stimulated with: interleukin-
1 beta (IL-1b) (20 ngml 1), tumour necrosis factor-a (TNF-a)
(20 ngml 1) and interferon-g (IFN-g) (500 units per ml), inter-
leukin-6 (IL-6), and transforming growth factor-b (TGF-b)
(10 ngml 1) (Peprotech, Rocky Hill, NJ, USA) for 8 h. Expression
of CX3CR1 and CX3CL1 was assessed by qRT-PCR, as previously
described by using primers for murine CX3CR1 50-ATTCTTCAT
CACCGTCATCAG-30, 50-ACTAATGGTGACACCGTGCT-30 and
for murine CX3CL1 50-GCTATCAGCTAAACCAGGAGTC-30,
50-AGAAGCGTCTGTGCTGTGTC-30.
Three-dimensional cell culture, immunofluorescence, and cell
transplantation in syngenic mice. DT6606, K8484, A8184, and
AspCI cells were mixed with Cultrex (5 104 cells per 250 ml) and
plated in a 24-well plate. Cells were fixed overnight in 4% PFA,
washed twice with PBS / plus 0.2% Tween. Immunofluores-
cence was performed after blockade of endogeneous non-specific
antigens and permeabilisation by PBS / plus 10% normal goat
serum, and 0.03% Triton. Cells were treated with primary
antibodies raised against CX3CR1 (Ab8021; Abcam) overnight at
4 1C, washed, and incubated with secondary antibody 1 : 2000
Alexa-fluor-488 (Invitrogen) for 1 h at room temperature. Sub-
sequently, cells were incubated with 1 : 50 dilution of Alexa-fluor-594
phalloidin (Invitrogen). Nuclei were counterstained with DAPI
(Invitrogen) 1 : 10.000. Imaging was obtained by confocal micro-
scopy (Olympus, Tokyo, Japan). For RT–PCR analysis, mRNA
from spheroid in culture was extracted by Trizol (Applied
Biosystem), according to the manufacturer instruction, RT and
analysis were performed as above described.
DT6606, K8484, and PANC02 cells were transplanted in
syngenic C57BL/6 mice. We took advantage of a porous collagen
biocompatible matrix, which provide a three-dimensional spatial
architecture scaffold for the cells (Collagen Sponge CS-35; KOKEN
Co Ltd, Tokyo, Japan). Collagen Sponges were loaded with
DT6606, K8484, and PANC02 cells (106 per ml) and intradermally
injected in 15, 8, and 5 C57BL/6 mice, respectively, by a small
incision on the left flank. Mice were killed after 2 weeks and
tumours were immediately resected and fixed in formalin.
Statistical analysis. Categorical associations between expression of
CX3CR1 and CX3CL1 and clinical-pathological factors of PDAC
were analysed by Chi-square (or Fisher’s test, when appropriate),
while Student’s T-test was employed for continuous variables.
Kaplan–Meier curves of OS were plotted. The log-rank test was
used to compare the curves of patient subgroups. A Cox
proportional hazards model was constructed to assess the role of
fractalkine and its receptor in predicting the OS.
Analyses were done using Epi Info version 3.5.1 (Centers for
Disease Control and Prevention (CDC), Atlanta, GA, USA) and
STATISTICA 7.1 (StatSoft, Tulsa, OK, USA). For each test, only
two-sided P-values lower than 0.05 were considered as statistically
significant.
RESULTS
CX3CR1 expression in PDAC is associated with tumour
glandular differentiation and PNI. We previously showed that
the chemokine receptor CX3CR1 is upregulated in pancreatic cancer
compared with normal exocrine tissue, and that receptor expression
was involved in tumour PNI (Bazan et al, 1997). In this study, we
investigated in an independent cohort whether the specific ligand
CX3CL1 is also expressed in PDAC, and whether both molecules are
upregulated already in pre-neoplastic lesions (PanINs).
In normal pancreas, CX3CR1 expression by IHC was faint to
negative in exocrine cells but positive in endocrine islets
(Figure 1A). Conversely, cancer cells in 56 of 104 (53.9%) PDAC
expressed CX3CR1. In PDACs, CX3CR1 expression was associated
with a well-to-moderate differentiation (65.1% of CX3CR1þ in
G1/G2 PDAC vs 37.5% CX3CR1þ in G3 PDAC; P¼ 0.005)
(Figure 1B and C), as well as with the presence of PNI (63.1% of
CX3CR1þ neural-invasive PDAC vs 38.5% of CX3CR1þ non-
neural-invasive PDAC, P¼ 0.01) (Table 1), this latter being not
associated with tumour grade. Notably, in our series the presence
of PNI was not associated with tumour differentiation (40 of 63,
63.5%, G1–G2 neuroinvasive cancers vs 24 out of 40, 60%, G3
neuroinvasive ones, P¼ 0.44). In addition, by stratifying cancers
according to their differentiation we found that CX3CR1þ
differentiated tumours were more frequently neural invasive
(30 out of 40, 75%) than CX3CR1 cancers (10 out of 23, 43.5%;
P¼ 0.008), while in poorly differentiated cases the frequency of
PNI was similar in CX3CR1þ (10 out of 15, 66%) and in
CX3CR1 cancers (14 out of 25, 56%; P¼ 0.37) (Figure 1G).
In the tumour microenvironment, vessels and infiltrating
inflammatory cells were also CX3CR1þ (Figure 1B, inset).
In non-neoplastic pancreas, CX3CL1 was faintly expressed in
exocrine cells and endocrine islets, and expressed by neural cell
bodies (Figure 1D and E) but not by neural processes. In all, 70 of
104 (67.3%) PDAC showed immunoreactivity for CX3CL1
(Figure 1F). No significant correlation was found between CX3CL1
expression and cancer features (Table 1), but the ligand was more
frequently expressed in CX3CR1þ (45 out of 56, 80.3%) than in
CX3CR1– (23 out of 48, 51.1%; P¼ 0.002) PDAC.
At multivariate analysis, better tumour differentiation (P¼ 0.008),
PNI (P¼ 0.03), and ligand expression (P¼ 0.003) were all
independently associated with CX3CR1 expression (Table 2).
CX3CR1 expression in cancer is associated with better patient
survival. We assessed patient survival according to CX3CR1 and
CX3CL1 status in PDAC. Patients with CX3CR1þ PDAC had a
longer survival (mean 22.6 months; 95% CI, 15.7–29.5 months)
than patients with receptor-negative cancers (14.45 months; 95% CI,
11.0–17.8 months), although the difference was not statistically
significant (log-rank test, P¼ 0.07). However, considering only
patients with radical surgery and no surgery-related mortality, those
with CX3CR1þ PDAC had a significantly better survival
(31.95 months; 95% CI, 22.7–41.2 months) than those with
CX3CR1-immunonegative cancers (18.9 months; 95% CI, 14.9–
22.9 months; log-rank test, P¼ 0.05) (Figure 1H). No survival
difference was observed according to CX3CL1 status in PDAC
(P¼ 0.95). In this set of patients, the analysis by Cox proportional-
hazard model showed that the tumour expression of CX3CR1 was
associated with a better survival (HR 0.56, 95% CI, 0.32–1.00;
P¼ 0.05), independently of tumour grade and PNI. Adjusting the
model by tumour stage resulted in a loss of statistical significance,
although patients with CX3CR1þ PDACs retained tendency to
better survival (HR 0.58, 95% CI, 0.32–1.04; P¼ 0.07).
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Precursor lesions of pancreatic cancer express CX3CR1 and
CX3CL1. We evaluated receptor and ligand status in PanINs to
assess whether their expression appears before an invasive stage. In
our series, 76 (73.1%) PDAC specimens harboured precursor
lesions. Precursor lesions were in general more frequently positive
for CX3CR1 than PDACs (61, 80.3% vs 42, 55.3%, respectively;
P¼ 0.002), and specifically PanINs in specimens of undifferen-
tiated G3 cancers were more frequently CX3CR1þ than PDAC
(22 out of 28, 78.6% vs 10 out of 28, 35.6%, respectively; P¼ 0.001)
(Figure 2A). CX3CL1 was also strongly upregulated in PanINs
(40 out of 48, 83.3%) (Figure 2A) and, as observed for the receptor,
ligand expression was higher in PanINs (26 out of 28, 92.9%) than
in associated G3 PDACs (17 out of 28, 60.7%; P¼ 0.005)
(Figure 2A).
Next, we studied ligand and receptor expression in precursor
lesions according to their degree of dysplasia, characterised by
morphological analysis and molecular phenotype (E-Cadherin and
p16/CDKN2A; Supplementary Figure S1). Of 15 PDAC specimens
analysed, 8 out of 8 G1–G2 tumours were CX3CR1þ , while 3 out
of 7 G3 tumours were CX3CR1þ . In the set of graded PanINs, the
frequency of CX3CR1þ precursor lesions increased from
PanINs-1 to through PanINs-3 (Po0.001; Figure 2B); conversely,
CX3CL1 expression decreased from PanIN-1 through PanIN-2 and
PanIN-3 (P¼ 0.003; Figure 2B). Representative images of CX3CR1
and CX3CL1 immunohistochemical staining in human PanINs are
shown in Figure 3A.
Overall, upregulation of both CX3CR1 and CX3CL1 is an early
feature of pancreatic carcinogenesis, being expressed already in
PanINs-1. While positivity for both molecules is maintained
through carcinoma stage if PDAC retains well-to-moderate
differentiation, poorly differentiated tumours tend to lose their
expression. These results indicate that the expression of the
CX3CL1/CX3CR1 axis is a distinguishing feature of tumours with
glandular morphology.
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Figure 1. CX3CR1 and CX3CL1 expression in normal pancreas and in pancreatic cancer. (A) CX3CR1 expression in normal pancreas, (B) in well-
and (C) in poorly differentiated PDAC, and (B, inset) in inflammatory cells in tumour microenvironment. (D) CX3CL1 expression in normal pancreas,
(E) in neural cell bodies, and (F) in PDAC (box, 40 magnification of a CX3CL1þ PDAC). Objective magnification 10 (A–D and F); (E) and inset
in (B), 40. (G) Frequency of CX3CR1þ and CX3CR1 PDAC with PNI according to tumour differentiation (Grade, G1–G2 well-to-moderately
differentiated PDAC; G3, poorly differentiated PDAC). (H) Kaplan–Meier curves for overall survival of patients after radical resection of PDAC
(n¼67), according to the status of CX3-CR1 (left panel) and -CL1 (right panel) in cancer. P-values by log-rank test. *indicates Po0.05.
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To confirm these findings, we studied precursor lesions in the
PdxCre/LSL-KrasG12D mouse model of pancreatic cancer. As in
humans, the normal exocrine pancreas of mice killed before the
development of precursor lesions (o6 months) did not show
CX3CR1 or CX3CL1 expression. Differently, CX3CR1 and
CX3CL1 were expressed in the PanINs of mice older than 6
months of age, irrespectively of the degree of dysplasia (Figure 3B).
To evaluate whether precursor lesions can mimic PNI, we
stained the pancreata of five PdxCre/LSL-KrasG12D mice with anti-
S-100. Immunostaining revealed a small fraction (13 of 400; 3.25%)
of precursor lesions either in proximity of, or in contact with,
neural structures (Figure 3B).
CX3CR1 is unresponsive to inflammatory stimuli, but its
expression is enhanced in spheroids in vitro, and in well-
differentiated tumour glands in vivo. We tested the responsiveness
of CX3CR1 and -CL1 expression to cytokines in pancreatic tumour
cells. In DT6606 cells, derived from tumours arising in PdxCre/
LSL-KrasG12D mouse model, and in K8484 cells, derived from
tumours of PdxCre/LSL-KrasG12D-Trp53R172H model, the only
observed change in CX3CR1 mRNA levels was a decrease following
TNF-a plus IFN-g treatment in DT6606 cells. Differently, TNF-a
plus IFN-g increased while TGF-b downregulated the expression of
CX3CL1mRNA in both murine tumour cell lines, an effect obtained
also by IL-1b and IL-6 treatment in K8484 cells (Figure 4).
In human PDAC cells (A8184, AspCI, and MiaPacaII),
inflammatory cytokines did not affect the mRNA levels of the
receptor, but TNF-a plus IFN-g and IL-1b strongly increased
the expression of the ligand. Like in cells derived from PdxCre/
LSL-KrasG12D and -KrasG12D-Trp53R172H, IL-6 and TGF-b
stimulation downregulated the ligand in A8184 and AspCI cells
(Figure 4).
The preferential expression of CX3CR1 in precursor lesions
and differentiated PDAC, together with the lack of responsive-
ness to inflammatory signals, suggests that glandular differentia-
tion may affect CX3CR1 status. Accordingly, we tested whether
the formation of gland-like structures can induce CX3CR1
expression in vitro. DT6606 and K8484 cells propagation as
Table 1. CX3CR1 and CX3CL1 expression in 104 PDAC according to patients’ demographics and to tumour features
Expression in PDAC
CX3CR1 CX3CL1
Negative
n¼48 (46.1%)
Positive
n¼56 (53.9%) Pa
Negative
n¼34 (32.7%)
Positive
n¼70 (67.3%) Pa
Patient age (years, mean±s.d.) 65.6±9.4 63.9±7.6 0.29 63.4±9.5 65.3±7.9 0.28
Patient gender
Male 30 (47.6) 32 (52.4) 0.36 20 (31.7) 43 (68.3) 0.48
Female 18 (43.9) 23 (56.1) 14 (34.1) 27 (65.9)
Tumour location
Head 40 (47.1) 45 (52.9) 1.00 29 (34.1) 56 (65.9) 0.51
Body-tail 9 (47.4) 10 (52.6) 5 (26.3) 14 (73.7)
Tumour invasion
pT1–T2 4 (40.0) 6 (60.0) 0.55 4 (40.0) 6 (60.0)
pT3 41 (45.6) 49 (54.4) 28 (31.1) 62 (68.9) 0.64
pT4 3 (75.0) 1 (25.0) 2 (50.0) 2 (50.0)
Nodal metastasis
N0 3 (25.0) 9 (75.0) 0.29b 3 (25.0) 9 (75.0) 0.22b
Nþ 35 (50.7) 34 (49.3) 25 (36.2) 44 (63.8)
Nx 10 (43.5) 13 (56.5) 6 (26.0) 17 (64.0)
Tumour gradec
G1–G2 23 (36.5) 40 (63.5) 0.005 21 (33.3) 42 (66.7) 0.47
G3 25 (62.5) 15 (37.5) 13 (32.5) 27 (67.5)
Tumour diameter (cm, mean±s.d.) 3.6±2.1 3.7±1.5 0.94 3.5±1.9 3.7±1.7 0.66
Neural invasion
No 24 (61.5) 15 (38.5) 0.01 15 (31.2) 24 (68.8) 0.39
Yes 24 (36.9) 41 (63.1) 19 (29.3) 46 (70.7)
Vascular invasion
No 23 (43.4) 30 (56.6) 0.28 18 (34.0) 35 (66.0) 0.39
Yes 25 (49.0) 26 (51.0) 16 (31.4) 35 (68.6)
Abbreviation: PDAC¼pancreatic ductal adenocarcinoma.
aBy chi-square or Fisher’s exact test as appropriate, except for patients’ age and tumour diameter comparisons, for which Student’s t-test was used.
bP-values of frequency distribution assessed in 81 (75.9%) PDAC with reliable nodal staging.
cNot determined in one PDAC, treated with neo-adjuvant radio-chemio-therapy.
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spheroids showed a spontaneous and significant CX3CR1 mRNA
and protein increase as compared with monolayer cell culture, in
which o5% and 20% of cells, respectively, were CX3CR1þ .
Immunofluorescence revealed a uniform CX3CR1 expression in
the cells positioned in the outer portion of the glandular
structure formed by DT6606 and K8484 spheroids. The same
immunepositivity was detectable in human cancer AspCI cell
spheroids, while in A8184 cells, receptor expression was not
significantly increased in spheroids with respect to monolayers
(Figure 5A–D).
To confirm the association between glandular differentiation
and CX3CR1 expression, we grafted pancreatic tumour cells in
syngenic C57BL/6 mice. Subcutaneous injection of DT6606 cells
in 15 mice and of K8484 cells in 8 mice ensued in tumour growth
in 11 (73.3%) and in 8 (100%) animals, respectively. The resulting
tumours were well differentiated and showed intense and
homogeneous CX3CR1 immunostaining. Differently, PANC02
cells efficiently propagated as undifferentiated cancers in 5 out of
5 mice, but none of these cancers expressed the receptor
(Figure 5E).
DISCUSSION
Our extensive studies in human pancreatic cancer and precursor
lesions, in a genetic mouse model, as well as in vitro and in vivo,
elucidate important aspects of CX3-CR1-CL1 expression in
pancreatic carcinogenesis. First, we found that human PanINs
and well-differentiated PDACs express CX3CR1 more frequently
than poorly differentiated cancers. Furthermore, CX3CR1
expression was significantly associated with PNI only in
differentiated PDAC. The presence of the receptor already in
pre-invasive precursor lesions indicates an early timing of
expression in pancreatic carcinogenesis. Such an early appearance
was experimentally mirrored by the results in the animal model.
Next, the presence of the receptor in differentiated cancers would
equip soon these tumours with the capability to follow a
chemotactic drive, contributing to PNI (Marchesi et al, 2008).
On the other side, our findings imply that poorly differentiated
PDACs do not take advantage of CX3CL1-driven chemotaxis and
adhesion in their spread. Such a difference in the expression of
chemotactic receptors depending upon tumour differentiation is
not restricted to CX3CR1, as CXCR7 was conversely found to be
more frequently expressed in poorly differentiated pancreatic
cancers (Gebauer et al, 2011). Accordingly, tumour grade, an
important determinant in PDAC outcome (Luttges et al, 2000;
Helm et al, 2009), accounts for the differential expression of
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Figure 2. Expression of CX3CR1 and CX3CL1 in precursor lesions
according to tumour differentiation and PanIN degree.
(A) Comparison of the expression rate of CX3CR1 (upper panels) and
CX3CL1 (lower panels) in paired precursor lesions and invasive cancers
within the same tissue specimens (n¼ 76), according to the degree of
pancreatic cancer differentiation. Number within bars, number of
specimens. (B) Rates of CX3CR1þ (upper panels) and CX3CL1þ (lower
panels) PanINs according to their degree of dysplasia. Numbers within
bars, number of PanINs. G1–G2 tumours, left panels; G3 tumours, right
panels; P-values by Fisher’s exact test.
Table 2. Tumour differentiation, peri-neural invasion, and ligand
expression are independently associated with CX3CR1 expression
CX3CR1 expression
OR 95% CI Pa
Tumour grade
G1–G2 1.0 Ref.
G3 0.30 0.12–0.73 0.008
Neural invasion
No 1.0 Ref.
Yes 2.63 1.08–6.39 0.03
CX3CL1 expression
Negative 1.0 Ref.
Positive 3.99 1.57–10.14 0.003
Abbreviations: CI¼ confidence interval; OR¼odds ratio.
aBy multivariate logistic regression analysis.
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chemokine receptors. As the precursor lesions in the context of
poorly differentiated PDAC expressed CX3CR1, we can infer
that cancer cells no longer express this receptor when clonal
selection privileges the outgrowth of undifferentiated clones. It is
thus conceivable that the sensitivity of pancreatic cancer
to chemokine attraction varies along tumour evolution
(Kim et al, 2005; Buckle et al, 2012), such as changes in tumour
differentiation.
The pro-invasive role of CX3CR1, which is foreseeable after
the transition from PanIN to invasive cancer, remains otherwise
elusive in pre-invasive lesions (Balkwill, 2012). In a mouse model
of pancreatic cancer, PanIN cells can cross the basement
membrane and delaminate in the microenvironment before
any invasive behavior can be detected by histological criteria,
indicating that PanINs may already harbour cells with invasive
features (Rhim et al, 2012). Such invasive and tumour initiating
cells from PanINs lacked E-Cadherin (Rhim et al, 2012), and in
keeping with this notion we found a marked decrease in
E-Cadherin expression in CX3CR1þ PanINs. Additional
studies should assess whether delaminating cells from PanINs
express CX3CR1, anticipating the involvement of chemotaxis
in PNI.
We have previously reported the association among CX3CR1
expression, marked PNI, and shorter progression-free survival
(Marchesi et al, 2008). In this independent cohort, we found that
patients with CX3CR1þ PDAC had a longer OS. Perineural
invasion is a predictor of tumour recurrence, but tumour grade is
the only histological feature of pancreatic cancer associated with
worse survival (Helm et al, 2009; Shimada et al, 2011).
Consistently, tumour grade, but not PNI, was a predictor of
patient survival in our series, and the tumour expression of
CX3CR1 retained prognostic value once adjusted for tumour grade
and stage in a Cox model. Thus, the association between CX3CR1
tumour expression and better patient survival may simply reflect
Human
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Figure 3. CX3CR1 and CX3CL1 expression in precursor lesions of pancreatic cancer. (A) Left panels, human PanINs; right panels, PanINs of
PdxCre/LSL-KrasG12D mice. Objective magnification,  20 (human PanINs), and  40 (mice PanINs). (B) Precursor lesions adjacent to neural
structures. Detection of precursor lesions close to (left panel) or in tight contact with (right panel) S-100þ neural structures (red arrows) in pancreata
of 6-month-old PdxCre/LSL-KrasG12D mice. Magnification, 20.
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an earlier disease. Differently, Xu et al (2012) reported that
CX3CR1 status in PDAC has no prognostic value, while CX3CL1
expression would predict a worse prognosis. In this series, however,
radical surgery was not considered, and average survival was
almost half than in our, implying that patients with rather
advanced disease have been studied. Considering that the invasive
profile drawn by chemokine receptors changes with tumour
evolution (Kim et al, 2005; Ottaiano et al, 2006), our results suggest
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that CX3CR1 could be foreseen as a biomarker paralleling early
invasiveness, a feature that innovative imaging techniques might
help to address (Buckle et al, 2012). If this were the case, then the
axis CX3-CR1-CL1 would be a candidate target for interfering with
invasion at the transition to invasive cancer.
In the second instance, our experimental results provide
support to the associative data. CX3CR1 was unresponsive to
inflammatory signalling in vitro, but was modulated by the
structural organisation of tumour cells, both in vitro and in vivo.
In parallel with findings in human PDAC, mouse tumour
DT6606 cells expressed CX3CR1 in vitro only if cultured as
spheroids, as they did in vivo growing as gland-forming tumours.
Conversely, growth of undifferentiated PANC02 cells resulted in
CX3CR1-negative cancers in vivo. Thus, experimental models
confirming that tumour differentiation is crucial in setting
CX3CR1 expression in tumour cell, reveal that the three-
dimensional organisation of neoplastic cells is a crucial factor
for the expression of a chemotactic receptor. Although we did not
investigate the signalling coupling the organisation of tumour
cells with CX3CR1 expression, our data underline that the
expression of the receptor is unlikely dependent upon micro-
environmental cross-talk, rather being determined by tumour
morphological features. Differently, CX3CL1 expression was
strongly driven by inflammation in vitro. Pro-inflammatory
TNF-a plus IFN-g induced a higher increase in CX3CL1 mRNA
in Kras-mutated than in isogenic but p53-mutated ductal cells,
confirming that p53 damage dampens CX3CL1 responsiveness
along tumour progression (Shiraishi et al, 2000; Algul et al, 2007;
Jones et al, 2008; Sipos et al, 2009). These results help to explain
for the reduced rate of CX3CL1 expression in PanINs with
increasing dysplasia, known to be coupled with P53 damage
(Remmers et al, 2011). The high rate of CX3CL1 expression in
PanINs-1 is consistent with other data showing that the
chemotactic recruiters of leukocytes appear with the first
intraepithelial stages of human pancreatic carcinogenesis,
decreasing thereafter (Hiraoka et al, 2011). The responsiveness
of CX3CL1 to cytokines observed in pancreatic tumour cells also
fits with its involvement in the tumour-stroma cross-talk
contributing to the desmoplasic reaction (Hiraoka et al, 2011),
as shown in chronic pancreatitis (Ceyhan et al, 2009). Joined with
previous findings (Thomas et al, 2008), our results firmly indicate
that the switch-on of chemotactic molecules is a common and
early feature of pancreatic carcinogenesis, encouraging the
development of strategies aimed to interfere with the CX3-CR1-
CL1 axis to constrain early on the invasiveness of differentiated
pancreatic cancer.
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